Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma

Neuropathol Appl Neurobiol. 2022 Apr;48(3):e12773. doi: 10.1111/nan.12773. Epub 2021 Dec 1.

Abstract

TERT promoter mutations have been associated with increased risk of recurrence in meningioma cohorts, thus a potential biomarker for aggressive phenotypes. A main purpose of refining tumour classification is better predictions on the patient level. We compiled data from previous published cohorts to investigate patient-level predictions of recurrence based on TERTp-mut status. Implementation of TERTp-mut into the WHO grading led to better patient prognostication by improved prediction of recurrence. Our results support implementation of TERTp-mut into diagnostics and classification of meningiomas.

MeSH terms

  • Humans
  • Meningeal Neoplasms* / genetics
  • Meningeal Neoplasms* / pathology
  • Meningioma* / genetics
  • Meningioma* / pathology
  • Mutation
  • Promoter Regions, Genetic / genetics
  • Telomerase* / genetics
  • World Health Organization

Substances

  • TERT protein, human
  • Telomerase